PepGen Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
PEPG Nasdaq 2830 www.pepgen.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for PepGen Inc.

PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program - May 21st, 2026 5:00 am
PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - May 20th, 2026 7:35 am
Is PepGen (PEPG) One of the Best NASDAQ Stocks Under $5 to Buy Right Now? - May 17th, 2026 10:49 pm
PepGen (PEPG) Upgraded to Buy: Here's What You Should Know - May 13th, 2026 10:00 am
PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - May 12th, 2026 2:05 pm
AstronauTx builds executive team with appointment of experienced clinical development leader Michelle Mellion, MD as Chief Medical Officer - May 12th, 2026 1:30 am
PepGen Reports Encouraging Phase II FREEDOM2 DM1 Data at 5 mg/kg; 10 mg/kg Cohort Underway - Mar 31st, 2026 6:07 pm
PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data - Mar 30th, 2026 2:05 pm
PepGen muscular dystrophy drug gets ‘surprise’ hold from FDA - Mar 5th, 2026 3:59 am
PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights - Mar 4th, 2026 2:05 pm
PepGen Announces Regulatory Updates on FREEDOM2 - Mar 4th, 2026 2:03 pm
PepGen to Participate in the Leerink Global Healthcare Conference - Mar 3rd, 2026 5:00 am
How Much Upside is Left in PepGen (PEPG)? Wall Street Analysts Think 75.44% - Dec 10th, 2025 7:55 am
PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Business and Legal Officer - Dec 9th, 2025 5:00 am
PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer - Dec 8th, 2025 5:00 am
Sarepta's Stock Rises on Positive Updates on DM1 Therapy - Nov 25th, 2025 11:08 am
PepGen Inc.'s (NASDAQ:PEPG) largest shareholders are individual investors with 39% ownership, private equity firms own 36% - Nov 15th, 2025 5:53 am
PepGen Announces Issuance of U.S. Patent for Proprietary PGN-EDODM1 Molecule - Nov 12th, 2025 5:05 am
PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - Nov 12th, 2025 5:00 am
PepGen to Participate in Upcoming Investor Conferences - Nov 3rd, 2025 5:00 am